The Janus kinase-signal transducer and activator of transcription (Jak-Stat) pathway stands as a paradigm of how diverse extracellular signals can elicit rapid changes in gene expression in specific target cells. This pathway is widely used by members of the cytokine receptor superfamily, including those for the clinically important cytokines granulocyte colony-stimulating factor (G-CSF), erythropoietin, thrombopoietin, the interferons, and numerous interleukins, which makes it central to hematopoietic cell biology and hematologic therapy alike. Indeed, study of the Jak-Stat pathway has provided a wealth of information on hematopoiesis and hematopoietic disease, and conversely, studies of hematopoietic disorders have yielded new insights into the functions of Jaks and Stats. This review aims to detail the role of the Jak-Stat pathway in the normal development and function of hematopoietic cells and to describe how several hematopoietic disorders are caused, at least in part, by perturbations of this pathway.

Jaks are cytoplasmic tyrosine kinases that participate in signaling from a range of cell-surface receptors, particularly members of the cytokine receptor superfamily, which lack intrinsic tyrosine kinase activity.1,2 There are 4 mammalian Jaks: Jak1, Jak2, Jak3, and Tyk2. These associate with the weakly conserved “box 1” and “box 2” recognition motifs in the membrane-proximal region of cytokine receptors3,4 and are responsible for a range of phosphorylation events on stimulation of such receptors with their specific ligand. In addition, some receptors that have tyrosine kinase activity, such as those for macrophage colony-stimulating factor and stem cell factor, also activate Jaks, though it is unclear what role they play in these instances.5 6 

Cell lines deficient for either Jak1 or Jak2 are unable to mediate a response to interferon-γ, whereas those deficient in Tyk2 fail to respond to interferon-α/β.7-9 In addition, the expression of kinase-deficient Jaks or the introduction of mutations that prevent Jak binding and activation abolishes the proliferative and anti-apoptotic signaling from a number of other cytokine receptors.10-14 The essential role of Jaks in mediating the effects of these hematopoietic regulators was recently confirmed by targeted disruption of the corresponding murine genes (Table1). Jak1-deficient mice exhibited perinatal lethality, apparently because of defective neural function, and defective lymphoid development.15 Targeted disruption of the Jak2 gene resulted in an embryonic lethal phenotype caused by a block in definitive erythropoiesis but with intact lymphoid development.16,17 In both cases, a number of other specific cytokine-induced biologic responses were absent or impaired. Finally, Jak3 knockout mice exhibited severe combined immunodeficiency, with markedly reduced numbers of functional T and B lymphocytes,18,19 and dysregulated myelopoiesis.20 Thus, the Jaks collectively are vital for normal hematopoietic function, which can be explained by their nonredundant role in the signaling of specific cytokines (Table1).

Table 1.

Jaks in hematopoiesis: phenotype of mouse knockouts

Jak Type Relevant Phenotypes Cytokines AffectedRefs
Jak1  •  Impaired lymphoid development  IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-15, LIF, all interferons  15  
 •  Defective responses to class 2 cytokines and those using γc or gp130 receptor subunits  
Jak2  •  No definitive erythropoiesis  EPO, TPO, IL-3, IL-5, GM-CSF, IFN-γ  16, 17  
Jak3  •  Defective lymphoid development  IL-4, IL-7, IL-9, IL-15  18-20 
 •  Dysregulated myelopoiesis 
Jak Type Relevant Phenotypes Cytokines AffectedRefs
Jak1  •  Impaired lymphoid development  IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-15, LIF, all interferons  15  
 •  Defective responses to class 2 cytokines and those using γc or gp130 receptor subunits  
Jak2  •  No definitive erythropoiesis  EPO, TPO, IL-3, IL-5, GM-CSF, IFN-γ  16, 17  
Jak3  •  Defective lymphoid development  IL-4, IL-7, IL-9, IL-15  18-20 
 •  Dysregulated myelopoiesis 

EPO, erythropoietin; IFN, interferon; IL, interleukin; TPO, thrombopoietin.

Stats are latent cytoplasmic transcription factors that become activated after recruitment to an activated receptor complex. Subsequently, these active Stats translocate to the nucleus to affect gene expression. Seven Stat proteins have been identified in mammalian cells—Stats1 to 6, including Stat5a and Stat5b, which are encoded by distinct genes. In addition, different isoforms of several Stats have been identified.21 

Targeted inactivation of Stat genes in the mouse also resulted in severe effects on the development and function of hematopoietic cells (Table 2). Stat1 knockout mice showed defective innate immune responses to viruses and bacteria because of the absence of interferon signaling,22,23whereas Stat2 knockout mice showed defective responses to interferon α/β (C. Schindler, personal communication, 1999). Targeted disruption of the Stat3 gene produced early embryonic lethality.24 Subsequently, T-cell–specific Stat3-deficient mice were generated that were severely impaired in IL-6–induced proliferation because of enhanced apoptosis.25,Stat4 knockout mice were defective in the formation of Th1 cells, largely a result of disrupted IL-12 receptor function.26,27 Mice with both Stat5a andStat5b genes disrupted showed multiple defects, with responses to IL-2, IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) affected,28,29 whereas the respective single Stat5knockouts also exhibited defective proliferative responses to specific cytokines.30,31 Finally, a block in Th2 cell development and IgE class switching was observed in Stat6 knockout mice.32 33 

Table 2.

Stats in hematopoiesis: phenotypes of mouse knockouts

Stat Type Relevant Phenotypes Cytokines Affected Refs
Stat1  •  Interferon responses absent: — innate immune responses absent — highly sensitive to viral/microbial infection — IFN-responsive genes not activated  IFNs only  22, 23  
Stat 2 •  Type 1 interferon responses impaired  IFN-α/β C. Schindler, pers. comm.  
Stat 3 •  Embryonic lethal   24  
Stat 4 •  IL-12 responses absent ↓  production of high IFN-γ, low IFN-γ Rα Th1 cells ↓  priming for high level IFN-γ production ↓  lymphocyte proliferation ↓  enhancement of NK cell-mediated cytotoxicity ↑  Th2 cells  IL-12 only 26, 27  
Stat5ab  •  Proliferation signaling affected: ↓  CFU-Mix, Eos, G, GM, Pre-B ↓  peripheral T cells Absence of NK cells  IL-2, IL-3, IL-7, GM-CSF, G-CSF  28, 29  
Stat6  •  IL-4 responses absent: -Absence of IL-4 producing Th2 cells -Block in B-cell IgE class switching ↓  lymphocyte proliferation (partial) ↓  expression of IL-4-induced cell surface markers  IL-4 only  32, 33, 179 
Stat Type Relevant Phenotypes Cytokines Affected Refs
Stat1  •  Interferon responses absent: — innate immune responses absent — highly sensitive to viral/microbial infection — IFN-responsive genes not activated  IFNs only  22, 23  
Stat 2 •  Type 1 interferon responses impaired  IFN-α/β C. Schindler, pers. comm.  
Stat 3 •  Embryonic lethal   24  
Stat 4 •  IL-12 responses absent ↓  production of high IFN-γ, low IFN-γ Rα Th1 cells ↓  priming for high level IFN-γ production ↓  lymphocyte proliferation ↓  enhancement of NK cell-mediated cytotoxicity ↑  Th2 cells  IL-12 only 26, 27  
Stat5ab  •  Proliferation signaling affected: ↓  CFU-Mix, Eos, G, GM, Pre-B ↓  peripheral T cells Absence of NK cells  IL-2, IL-3, IL-7, GM-CSF, G-CSF  28, 29  
Stat6  •  IL-4 responses absent: -Absence of IL-4 producing Th2 cells -Block in B-cell IgE class switching ↓  lymphocyte proliferation (partial) ↓  expression of IL-4-induced cell surface markers  IL-4 only  32, 33, 179 

CFU, colony-forming unit: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NK, natural killer.

Further evidence of the vital role of Stats in cytokine receptor signaling has been obtained from studies in cell lines. For example, a mutant cell line deficient in Stat1 expression showed a block in interferon signaling similar to that in Stat1 knockout mice.34 Other studies using dominant-negative Stats or specific receptor mutants have shown, for example, that Stat3 activation plays a key role in the differentiation responses to IL-6 and G-CSF,35-37 whereas Stat5 appears very important for proliferative responses to IL-3, IL-5, G-CSF, and GM-CSF38-40 and for neutrophilic differentiation in response to G-CSF.40 Interestingly, these latter studies differ from the relative mild effects on hematopoiesis seen inStat5ab double knockout mice,28 and they serve to highlight some of the potential problems in interpreting both model systems. For example, compensatory overlapping pathways can mask the physiological consequences of a gene disruption in a whole animal, whereas effects seen in cell lines may represent physiologically irrelevant endpoints or nonspecific consequences of a presumed dominant-negative protein acting on other pathways. However, both types of studies have together yielded great insight into the biologic function of Stats.

A general model of Jak-Stat activation from cytokine receptors has been proposed,2,21,41 though there are several exceptions and variations on the basic theme first elucidated for the interferon receptors.42 Binding of ligand to a cytokine receptor leads to the activation of Jaks, presumably through autophosphorylation on tyrosines (Figure 1). Activated Jaks then phosphorylate the receptor, creating docking sites for specific signaling proteins, including Stat proteins, which the Jaks can then phosphorylate on a conserved tyrosine residue at their C-terminus. Subsequently, the Stats form stable homodimers and heterodimers by interactions between the Src homology 2 (SH2) domain of one Stat protein and the phosphotyrosine of another before translocation to the nucleus, where they influence transcription of target genes by binding to specific regulatory sequences.21 41 

Fig. 1.

Activation of the Jak-Stat pathway by cytokine receptors and its regulation by CIS family members and tyrosine phosphatases.

Fig. 1.

Activation of the Jak-Stat pathway by cytokine receptors and its regulation by CIS family members and tyrosine phosphatases.

Close modal

Specificity in cytokine signaling is largely determined by the combination of activated Jaks and Stats. A wide range of cytokines and growth factors activate Jak1, Jak2, and Tyk, whereas Jak3 is only activated by cytokines that have the common γ-chain as a component of their receptor complex.43 Receptors show more specificity in their ability to recruit and activate Stats. For example, stimulation with interferon (IFN)-α or IFN-β leads to phosphorylation of Stats 1 and 2, which form a complex with a third protein, p48.44 In contrast, G-CSF stimulation leads to the activation of Stat3 and Stat5 homodimers, some Stat1 homodimers, and Stat1/3 and Stat3/5 heterodimers.45,46 Such studies have led to the suggestion that diversity within the type of Stat complexes activated contributes to the nature of the cellular responses to a given cytokine or growth factor.47 The subsequent gene knockout and dominant-negative mutant studies described above have largely supported this hypothesis.

The specificity of Stat activation is partially mediated through their recruitment to specific cytoplasmic tyrosines of particular receptors through their SH2 domains. For example, tyrosine 440 in the cytoplasmic domain of the IFN-γ receptor α chain is responsible for recruitment and activation of Stat1,48 whereas tyrosines 578 and 606 of the IL-4-R are required for phosphorylation and activation of Stat6.49 Similarly, numerous studies have identified the YxxQ motif as a consensus Stat3 docking site, though it can bind to other motifs.45,50,51 In addition, several examples of Stat activation that do not require direct docking to receptor tyrosines have been reported. For instance, full activation of Stat1 by G-CSF or growth hormone and of Stat5 by G-CSF and GM-CSF occurs in the complete absence of receptor tyrosines.38,45,51,52 It has been proposed that Jak1 and Jak2 can specifically recruit and phosphorylate Stat1 and Stat5, respectively,53,54 which could explain their activation in these cases. However, there is growing evidence that other receptor components can also act as docking sites for Stats.45,55 For example, Stat1 is recruited to the IFN-α/β receptor complex by binding to a Stat2 molecule already docked to the activated receptor.21 Thus, Stat specificity is determined by recruitment to the receptor complex in toto rather than simply to the linear sequence of each receptor. However, the particular Jaks and Stats activated may also be dependent on the cell-type or its state of differentiation,21,56-58 and receptor “cross-talk” may further modify the response elicited. For example, IL-4 inhibits IL-2–mediated Stat5 activation,59 IL-10 suppresses interferon-mediated Stat activation,60 and cyclic adenosine monophosphate impairs IL-2–dependent signaling by downregulating levels of the Jak3 protein itself.61 

Individual Stats bind to similar DNA response elements, mostly related to a γ interferon-activated site, a regulatory element in the promoter of IFN-γ–inducible genes.42 However, the recognition sites are not identical,62-64 and so different genes are targeted for induction by different Stats (Table3). In addition, Stats can mediate transcriptional repression at specific promoters.65,66 Some Stats are able to form both homodimers and heterodimers, which can further broaden the range of Stat/DNA-binding specificities.21 The duration of Stat activation is also able to influence the transcriptional program induced.21,46In addition, various Stat isoforms are differentially expressed in specific cell types, which can also have an impact on the expression of Stat-responsive genes.21,57,58,65 It has recently been shown that Stats can interact with a range of other nuclear factors and coactivators, including CBP, Nmi, the glucocorticoid receptor c-Jun, and MCM5,21,67-69 which increases the range of transcriptional responses in which Stats can participate. Finally, though phosphorylation of the C-terminal tyrosine is critical for Stat activation, serine phosphorylation probably also modulates the transcriptional response.70-73 Indeed, it was shown that Ser727 of Stat1α is directly involved in the recruitment of MCM5 as part of IFN-γ–induced transcriptional activation.68Together, this complex control of specificity enables an individual hematopoietic cell to elicit the appropriate transcriptional response to incoming signals from cytokines, growth factors, and other stimuli.

Table 3.

Genes induced by Stat proteins

Stat Genes Encoding Refs
Stat1  ISG54, IRF-1, CIITA, mig, 2,3 dioxygenase, GBP, p21  22, 23, 64  
Stat3  JunB, SAA3, JAB, C-reactive protein, BclxL, p21  63, 64, 98, 134, 136  
Stat4  IFN-γ, IRF-1, Fc-γRI, CD23, MHC class II  33, 180  
Stat5  β-casein, IL-2R-α, CIS, osm, pim1, p21, cyclin D1  92, 181-183  
Stat6  IL-4R-α, Fc-εRIIa, C-ε, C-γ1, C-γ4  21, 63, 64 
Stat1/Stat1/p48  GBP  64  
Stat1/Stat2/p48 (ISGF3) ISG15, ISG54, 6-16, 2′,5′ oligoadenylate synthetase, 2,3-dioxygenase  64 
Stat Genes Encoding Refs
Stat1  ISG54, IRF-1, CIITA, mig, 2,3 dioxygenase, GBP, p21  22, 23, 64  
Stat3  JunB, SAA3, JAB, C-reactive protein, BclxL, p21  63, 64, 98, 134, 136  
Stat4  IFN-γ, IRF-1, Fc-γRI, CD23, MHC class II  33, 180  
Stat5  β-casein, IL-2R-α, CIS, osm, pim1, p21, cyclin D1  92, 181-183  
Stat6  IL-4R-α, Fc-εRIIa, C-ε, C-γ1, C-γ4  21, 63, 64 
Stat1/Stat1/p48  GBP  64  
Stat1/Stat2/p48 (ISGF3) ISG15, ISG54, 6-16, 2′,5′ oligoadenylate synthetase, 2,3-dioxygenase  64 

IFN, interferon; IL, interleukin; MHC, major histocompatibility complex.

The major function of Jaks is generally considered to be Stat activation. However, this is clearly not the only role that Jaks play in signaling. For example, Jaks are directly implicated in the activation of the kinase Pyk2,74 stimulation of the Ras-MAPK pathway,13,75,76 and the induction of the c-fos and c-myc genes.77 Conversely, there is considerable evidence that some activation of Stats occurs independently of Jaks. For example, cell lines deficient in Jak2 or Tyk2 showed no effect on G-CSF–dependent Stat activation, and a cell line deficient in Jak1 showed only partial reduction in Stat3 activation.55 Similar results were obtained withJak knockout mice for a range of factors.16Furthermore, Stat6 activation after CD40 engagement occurs independently of detectable Jak phosphorylation.78 Such data suggest that other kinases are probably also involved in mediating Stat activation. In support of this, Src has been shown to bind and activate Stat3 directly,79 whereas Bcr-Abl can also recruit and activate Stat5 by the interaction of Stat5 with the adaptor CrkL, which itself docks to Bcr-Abl.80 Other work implicates a number of non-Jak kinases as responsible for the serine phosphorylation of Stats.73 81 

As further evidence of the importance of the Jak-Stat pathway, negative feedback mechanisms have been identified that control its activation (Table 4). These include endosomal degradation of Jak/receptor complexes through receptor-mediated endocytosis82,83 and the dominant-negative effects of several naturally occurring Stat variants.84,85 In addition, the PIAS proteins have been identified. They seem to bind directly to Stats and to inhibit DNA binding, though their exact biologic role remains unclear.72 86 Two other means of negative regulation, by CIS/SOCS/SSI family members and by tyrosine phosphatases, have been studied in more detail.

Table 4.

Negative regulatory mechanisms of the Jak-Stat pathway

Mechanism Refs
Receptor-mediated endocytosis  82, 83 
Dominant-negative Stats  84, 85  
PIAS family of proteins 72, 86  
CIS/SOCS/SSI family of proteins  88, 89  
Tyrosine phosphatases  114, 115 
Mechanism Refs
Receptor-mediated endocytosis  82, 83 
Dominant-negative Stats  84, 85  
PIAS family of proteins 72, 86  
CIS/SOCS/SSI family of proteins  88, 89  
Tyrosine phosphatases  114, 115 

CIS/SOCS/SSI Family

This family, variously called CIS, SOCS, or SSI, is a group of small proteins containing SH2 and CIS homology (CH) domains (also called SOCS boxes). At least 8 family members have been identified (CIS1 to CIS7 and JAB),87,88 which are involved in the relatively specific regulation of cytokine signaling.89 

The first member of this family, originally denoted CIS (now called CIS1) for cytokine-induced SH2-containing protein, was cloned as an immediate early gene that was induced by IL-2, IL-3, and erythropoietin.90,91 The induced CIS protein can subsequently associate with specific tyrosines of the activated receptors,92 including one of the major Stat5 binding sites of the erythropoietin receptor.93 Forced expression of CIS1 partially suppresses IL-3 or erythropoietin-induced proliferation and Stat5 activation.92 Conversely, Stat5 activates the CIS1 promoter through interaction with tandem TTCNNNGAA motifs,92 with CIS1 expression absent in the ovaries ofStat5ab double knockout mice.28 Thus, CIS1 appears to act as a negative feedback regulator of the Jak-Stat5 pathway. This is supported by recent observations in CIS1-transgenic mice that exhibited a phenotype similar to that observed in Stat5abdouble knockout mice.94 

The second CIS/SOCS/SSI family member, JAB (also called SOCS-1, SSI-1, and TIP-3), was identified independently because of its ability to interact with the kinase domains of Jak2 and Tec,95,96 to inhibit the IL-6–induced differentiation and growth arrest of a leukemic cell line,97 and to be recognized by an antibody to Stat SH2 domains.98 Overexpression of JAB can inhibit virtually any signal using Jaks, such as Stat5 activation by erythropoietin, Stat3 activation by leukemia inhibitory factor or IL-6, and c-fos induction by IL-2. However, JAB does not inhibit fibroblast growth factor (FGF)-induced c-fos activation or c-Kit phosphorylation, though it binds to the FGF receptor and c-Kit.87 Although JAB was found to suppress Tec kinase activity, this effect was marginal compared with its effect on Jaks. Therefore, JAB-mediated kinase inhibition seems to be specific for Jak tyrosine kinases; binding does not always imply inhibition. However, recently JAB has been shown to bind inducibly to the c-Kit receptor tyrosine kinase through its SH2 domain.95,99 Although JAB did not inhibit the catalytic activity of the c-Kit tyrosine kinase, it inhibited c-Kit–mediated proliferation signals, probably by interaction with the SH3 domains of the signaling proteins Grb2 and Vav, thereby suppressing their function.99 In certain circumstances JAB may also be able to suppress signals from non-Jak tyrosine kinases. JAB knockout mice displayed growth retardation, fatty degeneration of the liver, and monocytic infiltration of several organs. They died before weaning within 3 weeks of birth.100,101 Lymphocytes in the thymus and spleen of these mice exhibited accelerated apoptosis, and at 10 days of age their numbers were 20% to 25% of those in wild-type mice.100Among various pro-apoptotic and anti-apoptotic molecules examined, an upregulation of Bax was found in lymphocytes of the spleen and thymus of knockout mice.100 In addition, there was a progressive loss of maturing B lymphocytes in the bone marrow, spleen, and peripheral blood, whereas constitutive activation of Stat1 was found in the liver of JAB knockout mice.101 Part of this phenotype clearly resembles that found in IFN-γ–transgenic mice.102 In addition, hematopoietic progenitor cells from JAB knockout mice were hyperresponsive to IFN-γ, with the degree of inhibition varying markedly with the stimulating factor used.103 It is important to note that many of the pathologic conditions observed in JAB knockout mice can be eliminated by antibody injections or by crossing them with IFN-γ knockout mice.104 Therefore, JAB appears to act as a negative regulator of IFN-γ/Stat1 and probably functions by preventing apoptosis induced by Stat1. However, other studies suggest that JAB may also inhibit other pathways that induce Bax expression, thereby preventing Bax-induced apoptosis in vivo.100 

So how do the CIS family members exert their negative effects on Jak-Stat signaling? Several possibilities, which are not mutually exclusive, are shown in Figure 1. Among CIS family members, JAB and CIS3 are able to bind the Jak2 catalytic (JH1) domain,87leading to direct inhibition of the Jak kinase.105 Binding requires the SH2 domain plus an additional N-terminal 12 amino acids (extended SH2 subdomain) containing 2 residues (Ile68 and Leu75) that are conserved in the CIS family.14,105 This subdomain interacts with the tyrosine residue Y1007 in the activation loop of Jak2, whose phosphorylation is critical for the induction of kinase activity.106,107 Other CIS family members bind directly to receptors, where they may function by preventing stimulatory signaling pathways coupled to specific phosphotyrosine motifs on receptors.92,93 Alternatively, given that CIS proteins have a relatively short half-life, they may act as scavengers of activated receptor complexes, targeting them for degradation.93 In support of this, it has been shown that CIS1 itself is ubiquitinylated,93 whereas the CH domain appears to interact with components of the proteasomal degradation pathway.108-110 However, other studies have shown that the CH domain of JAB may actually protect this molecule from degradation.108 111 Clearly more work is required to unravel the various intracellular functions of the CIS family members.

Tyrosine phosphatases

Several studies have shown that an important negative regulatory mechanism of the Jak-Stat pathway involves the recruitment of tyrosine phosphatases containing tandem SH2 domains (SHP-1 and SHP-2) to receptor complexes. Both phosphatases can bind either activated receptors or to Jak family members themselves, leading to dephosphorylation of the kinase (Figure 1).112-115 This, in turn, leads to reduced activation of Jak-Stat pathway components.114,116 The potential in vivo importance of this mechanism is strongly suggested by the phenotype of motheaten(me/me) mice lacking SHP-1, which die of a disease with components of autoimmunity and inflammation.117 However, it remains to be elucidated whether enhanced Jak kinase activity is entirely responsible for the motheaten phenotype because SHP-1 has also been shown to regulate negatively a number of receptor and nonreceptor tyrosine kinases.118,119 In addition, though it is clear that the major means by which Stat activity is attenuated is through dephosphorylation by protein tyrosine phosphatases,21 it is unknown whether SHP-1 or SHP-2 or some other phosphatase is responsible. However, it appears that SHP-1 can associate directly with Stat5, implicating it in the direct dephosphorylation and deactivation of this Stat.120 

The wide use of the Jak-Stat pathway by hematologically important factors, the severity of artificially disrupting the Jak-Stat pathway on hematopoiesis, and the number of key genes with Stat-response elements already provides some appreciation of the importance of this pathway in hematopoiesis and the regulation of hematopoietic cell function. We will now summarize the studies showing that several diverse hematopoietic disorders exhibit perturbations in the Jak-Stat pathway. Indeed, in a number of these cases, experiments have directly implicated the altered Jak or Stat signaling, or both, in the pathogenesis of the disease. Such molecular investigations provide a foundation on which to build an understanding of these conditions and a framework for rational improvements in therapy.

Aberrant activation of Jaks and Stats

The most direct evidence implicating dysregulation of the Jak-Stat pathway in hematopoietic malignancies was the identification of Tel-Jak2 fusions in lymphoid and myeloid leukemias.121,122In early B-precursor acute lymphoblastic leukemia, t(9;12)(p24;p13) translocations were responsible, whereas in the case of atypical chronic myeloid leukemia there was a complex t(9;15;12)(p24;q15;p13) translocation. In each case, the helix-loop-helix oligomerization domain of the transcription factor Tel is fused to the catalytic JH1 domain of Jak2 (Figure 2), which leads to constitutive association and hence activation of the kinase and constitutive activation of Stat proteins.123,124 However, Jaks and Stats are also known to be constitutively activated in hematopoietic cells transformed by diverse oncogenic tyrosine kinases (Table 5), as well as in a variety of lymphomas and leukemias, including those transformed by oncogenic viruses (Table 6). For the oncogenic tyrosine kinases, the activation of Stats may be direct or occur through Jaks, whereas the oncogenic viruses activate a number of cytoplasmic kinases to mediate the constitutive Stat activation observed (Figure 3).125 

Fig. 2.

Tel-Jak2 fusions observed in myeloid (CML; chronic myeloid leukemia) and lymphoid (ALL; acute lymphoblastic leukemia) leukemias.121 122 

The relative position of the fusions, as well as the helix-loop-helix (HLH) and Jak homology (JH) domains are shown.

Fig. 2.

Tel-Jak2 fusions observed in myeloid (CML; chronic myeloid leukemia) and lymphoid (ALL; acute lymphoblastic leukemia) leukemias.121 122 

The relative position of the fusions, as well as the helix-loop-helix (HLH) and Jak homology (JH) domains are shown.

Close modal
Table 5.

Stat activation by specific oncoproteins

Cell type Oncoproteins Activated Stats Refs
Primary bone marrow  Bcr-Abl Tel-Jak2  Stat5 Stat5  184, 185 123, 124 
Myeloid cells  v-Src  Stats1,3,5  130  
Basophil/mast cells  Bcr-Abl  Stats1,5  129, 186  
Erythroleukemia/blast cells  Bcr-Abl  Stats1,5  129, 186, 187 
Pre-B lymphocytes  v-Abl  Stats1,5,6  188 
Cell type Oncoproteins Activated Stats Refs
Primary bone marrow  Bcr-Abl Tel-Jak2  Stat5 Stat5  184, 185 123, 124 
Myeloid cells  v-Src  Stats1,3,5  130  
Basophil/mast cells  Bcr-Abl  Stats1,5  129, 186  
Erythroleukemia/blast cells  Bcr-Abl  Stats1,5  129, 186, 187 
Pre-B lymphocytes  v-Abl  Stats1,5,6  188 
Table 6.

Activation of Jaks and Stats in hematopoietic malignancies

Type of Malignancy Activated Jaks and Stats Refs
Lyphoma  
 LSTRA T cell line  Jaks1,2; Stats3,5  115, 189  
 Cutaneous T-cell lymphoma  Jak3; Stats3,5  190 
 Mycosis fungoides  Stat3  191  
 Herpesvirus saimiri dependent  Stats1,3  131, 192  
 EBV-related  Stats1,3 193  
Leukemia  
 Erythroleukemia  Stats1,5  186 
 Acute myelocytic leukemia  Stats1,3,5  185, 193-196  
 Chronic myelocytic leukemia  Stat5  184, 185 
 Acute lymphocytic leukemia  Stats1,5  193, 194 
 Megakaryocytic leukemia  Stat5  197  
 HTLV-I dependent T-cell leukemia  Jaks1,3; Stats3,5 
Type of Malignancy Activated Jaks and Stats Refs
Lyphoma  
 LSTRA T cell line  Jaks1,2; Stats3,5  115, 189  
 Cutaneous T-cell lymphoma  Jak3; Stats3,5  190 
 Mycosis fungoides  Stat3  191  
 Herpesvirus saimiri dependent  Stats1,3  131, 192  
 EBV-related  Stats1,3 193  
Leukemia  
 Erythroleukemia  Stats1,5  186 
 Acute myelocytic leukemia  Stats1,3,5  185, 193-196  
 Chronic myelocytic leukemia  Stat5  184, 185 
 Acute lymphocytic leukemia  Stats1,5  193, 194 
 Megakaryocytic leukemia  Stat5  197  
 HTLV-I dependent T-cell leukemia  Jaks1,3; Stats3,5 

EBV, Epstein-Barr virus; HTLV, human T-cell lymphoma virus.

Fig. 3.

Mechanisms of aberrant Stat activation in hematopoietic malignancy and disease.

Fig. 3.

Mechanisms of aberrant Stat activation in hematopoietic malignancy and disease.

Close modal

Evidence for Jak-Stat involvement

Although the data above are suggestive of a positive role for constitutive activation of the Jak-Stat pathway in leukemia, the results are largely correlative. However, other studies have provided more direct evidence for this hypothesis. For example, overexpression of a Tel-Jak2 fusion is sufficient to render Ba/F3 cells factor-independent,121,123 and mice transplanted with retrovirus expressing this fusion develop a fatal mixed myeloproliferative and T-cell lymphoproliferative disorder with a latency of 2 to 10 weeks.123 In addition, 2 mutants of theDrosophila Jak kinase have been identified that lead to leukemia-like defects through hyperactivation of the kinase.126,127 Murine homologues of this Jak mutant have been further shown to induce leukemia in mice.127 Finally, inhibition of constitutive Jak2 phosphorylation in primary pre-B leukemic cells with the Jak2 inhibitor AG490 is able to inhibit cell proliferation.128 However, other studies suggest that the constitutive Jak activation seen in transformed cells is not actually required for transformation. Thus, dominant-negative Jaks are unable to inhibit either Stat5 activation or factor-independent cell proliferation induced by Bcr-Abl.129 In addition, v-Src can directly activate Stat3,130 whereas the Herpesvirus Tip protein co-associates Lck and Stat3, leading to constitutive Stat3 activation in T cells transformed by this virus,131suggesting that in these cases Jaks are also superfluous.

In contrast, numerous recent studies have provided strong evidence for a role of Stats in the transformation process. For example, a dominant-negative Stat5 was able to inhibit apoptosis-resistant, growth factor-independent proliferation and leukemic potential of Bcr-Abl transformed cells132,133 and of the growth factor-independent colony formation of primary mouse bone marrow progenitor cells transduced with Bcr-Abl retrovirus.132 In addition, a constitutively active Stat5 mutant could restore these functions to a mutant Bcr-Abl deficient in Stat activation.132 Similarly, the abrogation of IL-3 dependence of myeloid cells by v-Src requires the SH2 and SH3 domains, which specifies the activation of Stats,130 and dominant-negative Stat3 has been shown specifically to block v-Src transformation in other cell systems.134,135 Furthermore, studies in multiple myeloma cells that show constitutive Stat activation have revealed that dominant-negative Stat3 induces apoptosis,136 again implicating Stat3 in the transformation process. Finally, a constitutively active mutant of Stat5 is sufficient to induce factor independence of Ba/F3 cells.137 Thus, constitutive Stat activation appears necessary, and perhaps sufficient, for the transformation process.

The results of the above studies imply that a permanent alteration in the genetic program of transformed cells, achieved by the constitutive activation of Stat proteins, is a critical step in the transformation process. Recent studies have begun to shed light on those changes that may be important. Thus, constitutive expression of Jak2 in Ba/F3 cells has been shown to lead to the induction of Bcl-2, resulting in delayed cell death,138 but the constitutively activated Stat3 observed in bone marrow mononuclear cells from patients with multiple myeloma also confers resistance to apoptosis, this time through the induction of Bcl-xL.136 Identification of other genes involved in the transformation process remains an important goal for future research.

Alterations in the Jak-Stat pathway have been associated either directly or indirectly with other hematologic disease states.

Severe combined immunodeficiency

In the most common form of severe combined immunodeficiency (SCID), X-linked SCID, both cellular and humoral immunity are severely affected: T-cell development is arrested in the thymic cortex, there is an almost complete lack of circulating T lymphocytes, and, though B lymphocytes are present, they do not undergo class switching.139 In X-linked SCID, mutations have been identified in the gene encoding the common γ chain (γc), a constituent of a number of cytokine receptor complexes.140,141 Although these mutations occur at multiple positions, all mutant receptors are defective in the activation of Jak3.142,143 Indeed, Jak3 knockout mice display a SCID phenotype that is virtually indistinguishable from that of γc null mice.18,144 Moreover, in a less common autosomal-recessive form of SCID, patients have been reported with inactivating mutations in the Jak3 gene itself.4,145 146 Together these findings show that abrogation of the Jak-Stat pathway is sufficient to account for SCID in humans.

Severe congenital neutropenia/acute myeloid leukemia

Patients with severe congenital neutropenia (SCN) exhibit a severe reduction in circulating neutrophils and a maturation arrest of bone marrow progenitor cells at the promyelocyte/myeloid stage.147,148 Such patients have an increased risk for myelodysplasia, acute myeloid leukemia, or both, and a poor prognosis for survival.149,150 A subset of patients with SCN has been identified with acquired nonsense mutations in the gene encoding the G-CSF receptor, which truncate its carboxyl-terminus.151,152 This subset has a strong (around 50%) predisposition to acute myeloid leukemia. Mice carrying a similar G-CSF-R truncation also show reduced basal levels of circulating neutrophils, but on continuous G-CSF treatment, neutrophil counts become elevated to above those of wild-type controls because of the increased proliferation of myeloid progenitors.154 This suggests that the G-CSF-R truncation may contribute to SCN and to the subsequent development of acute myeloid leukemia in these patients. Bone marrow cells from these mutant mice show reduced Stat3 activation in response to G-CSF, even under saturating conditions. In addition, there is an altered dose-response of Stat3 compared to Stat5 activation, such that at lower G-CSF concentrations the Stat3 deficiency is even more pronounced, a result confirmed in myeloid 32D cells.45,155 Because Stat3 appears indispensable for differentiation responses to G-CSF, the reduced Stat3:Stat5 ratio in cells with truncated receptors at low G-CSF concentrations may contribute to the reduced maturation observed.45,154,155 In addition, molecular mechanisms have been identified recently that explain the hyperproliferative function of truncated G-CSF-R. Such receptors show defective internalization compared with wild-type receptors46,155,156 and have a concomitant extension in the activation of Stats, particularly Stat5,46 consistent with a previous report of enhanced Jak2 activation in patients with SCN (Figure 3).157 It has recently been shown in 32D cells expressing truncated G-CSF-R that dominant-negative Stat5 inhibits whereas dominant-negative Stat3 actually enhances G-CSF–mediated growth, implicating perturbed Stat5 activation as a key molecular determinant of the hyperproliferative responses elicited from truncated G-CSF-R (Ward et al, manuscript in preparation). In addition, a novel G-CSF-R mutation has been identified in a patient with SCN who was unresponsive to G-CSF therapy—in this case Stat5 activation was substantially reduced,158 again consistent with an important role of Stat5 in controlling proliferative responses to G-CSF.

Benign erythrocytosis

Benign erythrocytosis is a dominant autosomal condition characterized by a mild increase in red blood cell counts and normal serum levels of erythropoietin because of hypersensitivity to erythropoietin.159,160 In addition, there is an increased and a sustained activation of Jak2 and Stat5 after erythropoietin stimulation.112,160 A number of pedigrees have been identified, all of which lead to erythropoietin (EPO)-R truncations161,162 that invariably result in the loss of the binding site for SHP-1 at Tyr 449 of the EPO-R.112Because SHP-1 is a negative regulator of Jak2 activation by EPO, it appears that lack of SHP-1 activation is responsible for the altered Jak-Stat kinetics and enhanced EPO responses in these patients (Figure3).

Fanconi anemia

Fanconi anemia (FA) is an autosomal recessive chromosome instability syndrome characterized by progressive bone marrow failure and an increased susceptibility to malignancy.163,164 The FA group C gene (FAC) has been identified, with its disruption leading to profound hypersensitivity of hematopoietic precursor cells to IFN-γ in mice165 and in patients with FA group C.166This appears to be the result of sustained Stat1 activation leading to apoptosis of these cells.166 Other researchers have reported that the FAC protein is involved in the recruitment of Stat1 to the IFN-γ receptor complex,167 which further suggests that perturbed Stat1 activation contributes to the phenotype of this disease.

Interferon resistance

Interferons, particularly IFN-α, have important therapeutic applications in the treatment of hematologic malignancies, including CML, hairy cell leukemia, and cutaneous T-cell lymphoma (CTCL).168,169 However, the efficacy is limited by the development of clinical resistance to IFN therapy in these patients.169 Efforts to understand the molecular basis of IFN resistance have been made by generating somatic cell mutants resistant to IFN, which showed that defects in the IFN receptor, Jaks, or Stats could contribute to this phenomenon.21,42 Similar analysis of IFN-α–resistant derivatives of CTCL cells also revealed a defect in normal Jak-Stat responses caused by a total absence of Stat1 expression,170 as previously observed in patients with IFN-resistant melanoma.171 However, a recent study also suggests a possible role for JAB in IFN resistance, especially for patients with a dominant phenotype.172 Stable expression of JAB in either NIH-3T3 or M1 leukemic cells leads to resistance to IFN-γ– and IFN-β–induced growth arrest. In both cell systems, IFN-γ did not induce tyrosine phosphorylation and DNA-binding activity of Stat1. In addition, IFN-resistant clones derived from LoVo cells and Daudi cells were found to express high endogenous levels of JAB without stimulation, with a concomitant reduction in IFN-induced Stat1 and Jak phosphorylation.172 

Other diseases with altered Jak-Stat activation

Other hematologic diseases also show defects in the normal activation and regulation of Jak-Stat pathway components. For example, bone marrow cells from patients with myelodysplastic syndrome show impaired erythropoietin-induced Stat5 activation,173whereas reduced Tyk2/SHP-1 interaction has been observed in a kindred of familial hemophagocytic lymphohistiocytosis.174 However, additional experiments will be required to identify mechanisms by which these perturbations in the Jak-Stat pathway may contribute to the pathogenesis of disease.

It is clear from this review that the Jak-Stat pathway is perturbed in a variety of malignancies and hematopoietic disorders. There is also now solid evidence that constitutive activation of Jak-Stat pathway components plays an important role in transformation by Tel-Jak, Bcr-Abl, and v-Src and in multiple myeloma. Furthermore, the importance of defective Jak3 activation in SCID and of extended Stat5 activation in the hyperproliferative responses of truncated G-CSF-R is now established. However, the significance of altered Jak-Stat activation in the other disorders remains less clear. In each case, the judicious expression of dominant-negative or constitutively active Jak-Stat pathway components in either cell line or mouse models of these disorders should enable the relative contribution of altered Jak-Stat signaling to the disease phenotype to be established. In addition, the availability of numerous mouse strains either deficient or transgenic for specific Jak-Stat components provides additional opportunity for assessing their importance in vivo.

Much remains to be learned about structure/function relationships of Jaks and Stats and about the cross talk between the Jak-Stat pathway and other signaling pathways in hematopoietic cells. In addition, as outlined above, the definitive roles played by Stats in growth control and transformation must be determined. Furthermore, a complete understanding of the mechanisms by which the Jak-Stat pathway is negatively regulated remains an important goal. However, there is already much promise in applying the knowledge obtained on the Jak-Stat pathway and its perturbation for the development of innovative hematologic treatment strategies. As mentioned above, specific Jak inhibitors may have important clinical applications in acute lymphoblastic leukemia,128 and there is clear potential for using gene therapy to remedy Jak3 deficiency in SCID.175,176 Recent data providing the crystallographic structure of Stat1 and Stat3 complexed with DNA177 178opens the way for a finer understanding of Stat specificity at the molecular level, increasing the knowledge base required for designing suitable compounds for pharmacologic intervention. It is anticipated that future developments will further facilitate the translation of the basic science of the Jak-Stat pathway into the hematology clinic.

The authors apologize to colleagues whose works were not cited because of the size restrictions of the review.

Supported by an EMBO Long Term Fellowship and the NWO (A.C.W.) and by grants from the Ministry of Science, Education and Culture of Japan, the TORAY Research Foundation, and the Uehara Memorial Research Foundation (A.Y.).

Reprints:Alister C. Ward, Institute of Hematology, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR Rotterdam, Netherlands; e-mail: [email protected].

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Taniguchi
T
Cytokine signaling through nonreceptor protein tyrosine kinases.
Science.
268
1995
251
255
2
Ihle
JN
Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells.
Adv Cancer Res.
68
1996
23
65
3
Wells
JA
de Vos
AM
Hematopoietic receptor complexes.
Annu Rev Biochem.
65
1996
609
634
4
Cacalano
NA
Migone
TS
Bazan
F
et al
Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
EMBO J.
18
1999
1549
1558
5
Novak
U
Harpur
AG
Paradiso
L
et al
CSF-1 induced STAT activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts.
Blood.
86
1995
2948
2956
6
Deberry
C
Mou
S
Linnekin
D
Stat1 associates with c-kit and is activated in response to stem cell factor.
Biochem J.
327
1997
73
80
7
Müller
M
Briscoe
J
Laxton
C
et al
The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction.
Nature.
366
1993
129
135
8
Watling
D
Guschin
D
Muller
M
et al
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in interferon-gamma signal transduction.
Nature.
366
1993
166
170
9
Velazquez
L
Fellous
M
Stark
GR
Pellegrini
S
A protein tyrosine kinase in the interferon alpha/beta signaling pathway.
Cell.
70
1992
313
322
10
Miura
O
Cleveland
JL
Ihle
JN
Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors.
Mol Cell Biol.
13
1993
1788
1795
11
Quelle
FW
Sato
N
Witthuhn
BA
et al
Jak2 associates with the βc chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region.
Mol Cell Biol.
14
1994
4335
4341
12
Zhuang
H
Niu
Z
He
TC
Patel
SV
Wojchowski
DM
Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of Jak2.
J Biol Chem.
270
1995
14500
14504
13
Barge
RM
de Koning
JP
Pouwels
K
Dong
F
Löwenberg
B
Touw
IP
Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route.
Blood.
87
1996
2148
2153
14
Nicholson
SE
Willson
TA
Farley
A
et al
Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibtion of LIF and IL-6 signal transduction.
EMBO J.
18
1999
375
385
15
Rodig
SJ
Meraz
MA
White
JM
et al
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.
Cell.
93
1998
373
383
16
Parganas
E
Wang
D
Stravopodis
D
et al
Jak2 is essential for signaling through a variety of cytokine receptors.
Cell.
93
1998
385
395
17
Neubauer
H
Cumano
A
Muller
M
Wu
H
Huffstadt
U
Pfeffer
K
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.
Cell.
93
1998
397
409
18
Nosaka
T
van Deursen
JM
Tripp
RA
et al
Defective lymphoid development in mice lacking Jak3.
Science.
270
1995
800
802
19
Park
SY
Saijo
K
Takahashi
T
et al
Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.
Immunity.
3
1995
771
782
20
Grossman
WJ
Verbsky
JW
Yang
L
et al
Dysregulated myelopoiesis in mice lacking Jak3.
Blood.
94
1999
932
939
21
Darnell
JE
Jr
STATs and gene regulation.
Science.
277
1997
1630
1635
22
Meraz
MA
White
JM
Sheehan
KCF
et al
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.
Cell.
84
1996
431
442
23
Durbin
JE
Hackenmiller
R
Simon
MC
Levy
DE
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
Cell.
85
1996
443
450
24
Takeda
K
Noguchi
K
Shi
W
et al
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.
Proc Natl Acad Sci U S A.
94
1997
3801
3804
25
Takeda
K
Kaisho
T
Yoshida
N
Takeda
J
Kishimoto
T
Akira
S
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.
J Immunol.
161
1998
4652
4660
26
Thierfelder
WE
Van Deursen
J
Yamamoto
K
et al
Requirement for Stat4 in interleukin-12 mediated responses of natural killer cells.
Nature.
382
1996
171
174
27
Kaplan
MH
Sun
YL
Hoey
T
Grusby
MJ
Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice.
Nature.
382
1996
174
177
28
Teglund
S
McKay
C
Schuetz
E
et al
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.
Cell.
93
1998
841
850
29
Moriggl
R
Topham
DJ
Teglund
S
et al
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.
Immunity.
10
1999
249
259
30
Feldman
GM
Rosenthal
LA
Liu
X
et al
STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression.
Blood.
90
1997
1768
1776
31
Imada
K
Bloom
ET
Nakajima
H
et al
Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity.
J Exp Med.
188
1998
2067
2074
32
Takeda
K
Tanaka
T
Shi
W
et al
Essential role of Stat6 in IL-4 signalling.
Nature.
380
1996
627
630
33
Shimoda
K
van Deursen
J
Sangster
MY
et al
Lack of IL-4 induced Th2 response and IgE class switching in mice with disrupted Stat6 gene.
Nature.
380
1996
630
633
34
Müller
M
Laxton
C
Briscoe
J
et al
Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-α and -γ signal transduction pathways.
EMBO J.
12
1993
4221
4228
35
Nakajima
K
Yamanaka
Y
Nakae
K
et al
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells.
EMBO J.
15
1996
3651
3658
36
Shimozaki
K
Nakajima
K
Hirano
T
Nagata
S
Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells.
J Biol Chem.
272
1997
25,184
25,189
37
Ward
AC
Smith
L
de Koning
JP
van Aesch
Y
Touw
IP
Multiple signals mediate proliferation, differentiation and survival from the granulocyte colony-stimulating factor receptor in myeloid 32D cells.
J Biol Chem.
274
1999
14,956
14,962
38
Mui
AL-F
Wakao
H
O'Farrell
A-M
Harada
N
Miyajima
A
Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs.
EMBO J.
14
1995
1166
1175
39
Dong
F
Liu
X
de Koning
JP
et al
Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor.
J Immunol.
161
1998
6503
6509
40
Ilaria
RL
Jr
Hawley
RG
Van Etten
RA
Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation.
Blood.
93
1999
4154
4166
41
Horvath
CM
Darnell
JE
Jr
The state of the STATs: recent developments in the study of signal transduction to the nucleus.
Curr Opin Cell Biol.
9
1997
233
239
42
Darnell
JE
Jr
Kerr
IM
Stark
GR
JAK-STAT pathways and transcriptional activation in response to interferons and other extracellular signalling proteins.
Science.
264
1994
1415
1421
43
O'Shea
JJ
Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet?
Immunity.
7
1997
1
11
44
Schindler
C
Darnell
JE
Jr
Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.
Annu Rev Biochem.
64
1995
621
651
45
Ward
AC
Hermans
MHA
Smith
L
et al
Tyrosine-dependent and independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration.
Blood.
93
1999
113
124
46
Ward
AC
van Aesch
YM
Schelen
AM
Touw
IP
Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia.
Blood.
93
1999
447
458
47
Ihle
JN
Kerr
IM
Jaks and Stats in signaling by the cytokine receptor superfamily.
Trends Genet.
11
1995
69
74
48
Heim
MH
Kerr
IM
Stark
GR
Darnell
JE
Jr
Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway.
Science.
267
1995
1347
1349
49
Hou
J
Schindler
U
Henzel
WJ
Ho
TC
Brasseur
M
McKnight
SL
An interleukin-4-induced transcription factor: IL-4 Stat.
Science.
265
1994
1701
1706
50
Stahl
N
Farruggella
TJ
Bolton
TG
Zhong
Z
Darnell
JE
Yancopoulos
GD
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors.
Science.
267
1995
1349
1353
51
de Koning
JP
Dong
F
Smith
L
et al
The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation.
Blood.
87
1996
1335
1342
52
Wang
YD
Wong
K
Wood
WI
Intracellular tyrosine residues of the human growth hormone receptor are not required for the signaling of proliferation or Jak-STAT activation.
J Biol Chem.
270
1995
7021
7024
53
Shuai
K
Stark
GR
Kerr
I
Darnell
JE
Jr
A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ.
Science.
261
1993
1744
1746
54
Wakao
H
Gouilleux
F
Groner
B
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response.
EMBO J.
13
1994
2182
2191
55
Shimoda
K
Feng
J
Murakami
H
et al
Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor.
Blood.
90
1997
597
604
56
Avalos
BR
Parker
JM
Ware
DA
Hunter
MG
Sibert
KA
Druker
BJ
Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.
Exp Hematol.
25
1997
160
168
57
Caldenhoven
E
van Dijk
TB
Raaijmakers
JAM
Lammers
J-WJ
Koenderman
L
de Groot
RP
Activation of a functionally distinct 80-kDa STAT5 isoform by IL-5 and GM-CSF in human eosinophils and neutrophils.
Mol Cell Biol Res Comm.
1
1999
95
101
58
Caldenhoven
E
Buitenhuis
M
van Dijk
TB
et al
Lineage-specific activation of STAT3 by interferon-gamma in human neutrophils.
J Leukoc Biol.
65
1999
391
396
59
Castro
A
Sengupta
TK
Ruiz
DC
Yang
E
Ivashkiv
LB
IL-4 selectively inhibits IL-2-triggered Stat5 activation, but not proliferation, in human T cells.
J Immunol.
162
1999
1261
1269
60
Ito
S
Ansari
P
Sakatsume
M
et al
Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1.
Blood.
93
1999
1456
1463
61
Kolenko
V
Rayman
P
Roy
B
et al
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway.
Blood.
93
1999
2308
2318
62
Lamb
P
Seidel
HM
Haslam
J
et al
STAT protein complexes activated by interferon-γ and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties.
Nucl Acids Res.
23
1995
3283
3289
63
Seidel
HM
Milocco
LH
Lamb
P
Darnell
JE
Jr
Stein
RB
Rosen
J
Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity.
Proc Natl Acad Sci U S A.
92
1995
3041
3045
64
Decker
T
Kovarik
P
Meinke
A
GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression.
J Interferon Cytokine Res.
17
1997
121
134
65
Caldenhoven
E
van Dijk
TB
Solari
R
et al
STAT3 beta, a splice variant of transcription factor STAT3, is a dominant-negative regulator of transcription.
J Biol Chem.
271
1996
13,221
13,227
66
Luo
G
Yu-Lee
L
Transcriptional inhibition by Stat5: differential activities at growth-related versus differentiation-specific promoters.
J Biol Chem.
272
1997
26,841
26,849
67
Schaefer
TS
Sanders
LK
Nathans
D
Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3.
Proc Natl Acad Sci U S A.
92
1995
9097
9101
68
Zhang
JJ
Zhao
Y
Chait
BT
et al
Ser727-dependent recruitment of MCM5 by Stat1α in IFN-γ-induced transcriptional activation.
EMBO J.
17
1998
6963
6971
69
Zhu
M-H
John
S
Berg
M
Leonard
WJ
Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling.
Cell.
96
1999
121
130
70
Wen
Z
Zhong
Z
Darnell
JE
Jr
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
Cell.
82
1995
241
250
71
Zhang
X
Blenis
J
Li
H-C
Schindler
C
Chen-Kiang
S
Requirement of serine phosphorylation for formation of STAT-promoter complexes.
Science.
267
1995
1990
1994
72
Chung
CD
Liao
J
Liu
B
et al
Specific inhibition of Stat3 signal transduction by PIAS3.
Science.
278
1997
1803
1805
73
Jain
N
Zhang
T
Fong
SL
Lim
CP
Cao
X
Repression of Stat3 activity by activation of mitogen-activated protein kinase.
Oncogene.
17
1998
3157
3167
74
Miyazaki
T
Takaoka
A
Nogueira
L
et al
Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway.
Genes Dev.
12
1998
770
775
75
Schiemann
WP
Bartoe
JL
Nathanson
NM
Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase: evidence for participation of multiple signaling pathways which converge at Ras.
J Biol Chem.
272
1997
16,631
16,636
76
Mizuguchi
R
Hatakeyama
M
Conditional activation of Janus kinase (JAK) confers factor independence upon interleukin-3-dependent cells: essential role of Ras in JAK-triggered mitogenesis.
J Biol Chem.
273
1998
32,297
32,303
77
Watanabe
S
Itoh
T
Arai
K
Roles of JAK kinase in human GM-CSF receptor signals.
Leukemia.
11(suppl 3)
1997
76
78
78
Karras
JG
Wang
Z
Huo
L
Frank
DA
Rothstein
TL
Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement.
J Immunol.
159
1997
4350
4355
79
Cao
X
Tay
A
Guy
GR
Tan
YH
Activation and association of Stat3 with Src in v-Src-transformed cell lines.
Mol Cell Biol.
16
1996
1595
1603
80
Rhodes
J
York
RD
Tajinda
K
Tara
D
Druker
BJ
Analysis of CrkL and Stat5 interactions in Bcr-Abl-expressing cells [abstract].
Blood.
92
1998
476a
81
Yamashita
H
Xu
J
Erwin
RA
Farrar
WL
Kirken
RA
Rui
H
Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells.
J Biol Chem.
273
1998
30218
30224
82
Kim
TK
Maniatis
T
Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway.
Science.
273
1996
1717
1719
83
Strous
GJ
van Kerkhof
P
Govers
R
Ciechanover
A
Schwartz
AL
The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.
EMBO J.
15
1996
3806
3812
84
Wang
D
Stravopodis
D
Teglund
S
Kitazawa
J
Ihle
JN
Naturally occurring dominant negative variants of Stat5.
Mol Cell Biol.
16
1996
6141
6148
85
Azam
M
Lee
C
Strethlow
I
Schindler
C
Functionally distinct isoforms of STAT5 are generated by protein processing.
Immunity.
6
1997
691
701
86
Liu
B
Liao
J
Rao
X
et al
Inhibition of Stat1-mediated gene activation by PIAS1.
Proc Natl Acad Sci U S A.
95
1998
10,626
10,631
87
Masuhara
M
Sakamoto
H
Matsumoto
A
et al
Cloning and characterization of novel CIS family genes.
Biochem Biophys Res Comm.
239
1997
439
446
88
Hilton
DJ
Richardson
RT
Alexander
WS
et al
Twenty proteins containing a C-terminal SOCS box form five structural classes.
Proc Natl Acad Sci U S A.
95
1998
114
119
89
Yoshimura
A
The CIS family: negative regulators of JAK-STAT signaling.
Cytokine Growth Factor Rev.
9
1998
197
204
90
Yoshimura
A
Ohkubo
T
Kiguchi
T
et al
A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors.
EMBO J.
14
1995
2816
2826
91
Uchida
K
Yoshimura
A
Inazawa
J
et al
Molecular cloning of CISH, chromosomal assignment to 3p21.3, and analysis of expression in fetal and adult tissues.
Cytogenet Cell Genet.
78
1997
209
212
92
Matsumoto
A
Masuhara
M
Mitsui
K
et al
CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation.
Blood.
89
1997
3148
3154
93
Verdier
F
Chretien
S
Muller
O
et al
Proteasomes regulate erythropoietin receptor and STAT5 activation: possible involvement of the ubiquitinated CIS protein.
J Biol Chem.
273
1998
28,185
28,190
94
Matsumoto
A
Seki
Y
Kubo
M
et al
Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2 protein-1 (CIS1) transgenic mice.
Mol Cell Biol.
19
1999
6396
6407
95
Endo
TA
Masuhara
M
Yokouchi
M
et al
A new protein containing an SH2 domain that inhibits JAK kinases.
Nature.
387
1997
921
924
96
Ohya
KI
Kajigaya
S
Yamashita
Y
et al
SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase.
J Biol Chem.
272
1997
27178
27182
97
Starr
R
Wilson
TA
Viney
EM
et al
A family of cytokine-inducible inhibitors of signalling.
Nature.
387
1997
917
921
98
Naka
T
Narazaki
M
Hirata
M
et al
Structure and function of a new STAT-induced STAT inhibitor.
Nature.
387
1997
924
929
99
De Sepulveda
P
Okkenhaug
K
Rose
JL
Hawley
RG
Dubreuil
P
Rottapel
R
Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation.
EMBO J.
18
1999
904
915
100
Naka
T
Matsumoto
T
Narazaki
M
et al
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice.
Proc Natl Acad Sci U S A.
95
1998
15,577
15,582
101
Starr
R
Metcalf
D
Elefanty
AG
et al
Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1.
Proc Natl Acad Sci U S A.
95
1998
14,395
14,399
102
Young
HA
Klinman
DM
Reynolds
DA
et al
Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies.
Blood.
89
1997
583
595
103
Metcalf
D
Alexander
WS
Elefanty
AG
et al
Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1.
Leukemia.
13
1999
926
934
104
Nicola
NA
Nicholson
S
Metcalf
D
et al
Negative regulation of cytokine signaling by SOCS proteins [abstract]. LXIV Cold Spring Harbor Symposium on Quantitative Biology.
1999
237a
105
Yasukawa
H
Misawa
H
Sakamoto
H
et al
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop.
EMBO J.
18
1999
1309
1320
106
Liu
KD
Gaffen
SL
Goldsmith
MA
Greene
WC
Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Curr Biol.
7
1997
817
826
107
Weiss
A
Schlessinger
J
Switching signals on or off by receptor dimerization.
Cell.
94
1998
277
280
108
Kamura
T
Sato
S
Haque
D
et al
The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families.
Genes Dev.
12
1998
3872
3881
109
Zhang
J-G
Farley
A
Nicholson
SE
et al
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation.
Proc Natl Acad Sci U S A.
96
1999
2071
2076
110
Tyers
M
Willems
AR
One ring to rule a superfamily of E3 ubiquitin ligases.
Science.
284
1999
603
604
111
Narazaki
M
Fujimoto
M
Matsumoto
T
et al
Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.
Proc Natl Acad Sci U S A.
95
1998
13,130
13,134
112
Klingmüller
U
Lorenz
U
Cantley
LC
Neel
BG
Lodish
HF
Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals.
Cell.
80
1995
729
738
113
Fuhrer
DK
Feng
G-S
Yang
Y-C
Syp associates with gp130 and Janus Kinase 2 in response to interleukin-11 in 3T3-L1 mouse preadipocytes.
J Biol Chem.
270
1995
24,826
24,830
114
Jiao
H
Berrada
K
Yang
W
Tabrizi
M
Platanias
LC
Yi
T
Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1.
Mol Cell Biol.
16
1996
6985
6992
115
You
M
Yu
D-H
Feng
G-S
Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak-STAT pathway.
Mol Cell Biol.
19
1999
2416
2424
116
Carpenter
LR
Farruggella
TJ
Symes
A
Karow
ML
Yancopoulos
GD
Stahl
N
Enhancing leptin responses by preventing SH2-containing phosphatase 2 interaction with Ob receptor.
Proc Natl Acad Sci U S A.
95
1998
6061
6066
117
Shultz
LD
Schweitzer
PA
Rajan
TV
et al
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.
Cell.
73
1993
1445
1454
118
Plas
DR
Johnson
R
Pingel
JT
et al
Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling.
Science.
272
1996
1173
1176
119
Kozlowski
M
Larose
L
Lee
F
Le
DM
Rottapel
R
Siminovitch
KA
SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.
Mol Cell Biol.
18
1998
2089
2099
120
Ram
PA
Waxman
DJ
Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.
J Biol Chem.
272
1997
17,694
17,702
121
Lacronique
V
Boureux
A
Valle
VD
et al
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Science.
278
1997
1309
1312
122
Peeters
P
Raynaud
SD
Cools
J
et al
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
Blood.
90
1997
2535
2540
123
Schwaller
J
Frantsve
J
Aster
J
et al
Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
EMBO J.
17
1998
5321
5333
124
Ho
JM-Y
Beattie
BK
Squire
JA
Frank
DA
Barber
DL
Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Blood.
93
1999
4354
4364
125
Garcia
R
Jove
R
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling.
J Biomed Sci.
5
1998
79
85
126
Harrison
DA
Binari
R
Nahreini
TS
Gilman
M
Perrimon
N
Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.
EMBO J.
14
1995
2857
2865
127
Luo
H
Rose
P
Barber
D
et al
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways.
Mol Cell Biol.
17
1997
1562
1571
128
Meydan
N
Grunberger
T
Dadi
H
et al
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.
Nature.
379
1996
645
648
129
Ilaria
RL
Jr
Van Etten
RA
P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
J Biol Chem.
271
1996
31,704
31,710
130
Chaturvedi
P
Sharma
S
Reddy
EP
Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs.
Mol Cell Biol.
17
1997
3295
3304
131
Lund
TC
Prator
PC
Medveczky
MM
Medveczky
PG
The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells.
J Virol.
73
1999
1689
1694
132
Nieborowska-Skorska
M
Wasik
MA
Slupianek
A
et al
Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Srh homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
J Exp Med.
189
1999
1229
1242
133
de Groot
RP
Raaijmakers
JAM
Lammers
J-WJ
Jove
R
Koenderman
L
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Blood.
94
1999
1108
1112
134
Turkson
J
Bowman
T
Garcia
R
Caldenhoven
E
de Groot
RP
Jove
R
Stat3 activation by Src induces specific gene regulation and is required for cell transformation.
Mol Cell Biol.
18
1998
2545
2552
135
Bromberg
JF
Horvath
CM
Besser
D
Lathem
WW
Darnell
JE
Jr
Stat3 activation is required for cellular transformation by v-src.
Mol Cell Biol.
18
1998
2553
2558
136
Catlett-Falcone
R
Landowski
TH
Oshiro
MM
et al
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.
Immunity.
10
1999
105
115
137
Onishi
M
Nosaka
T
Misawa
K
et al
Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.
Mol Cell Biol.
18
1998
3871
3879
138
Sakai
I
Kraft
AS
The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells.
J Biol Chem.
272
1997
12,350
12,358
139
Voss
SD
Hong
R
Sondel
PM
Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.
Blood.
83
1994
626
635
140
Noguchi
M
Yi
H
Rosenblatt
HM
et al
Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans.
Cell.
73
1993
147
157
141
Puck
JM
Deschenes
SM
Porter
JC
et al
The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in severe combined immunodeficiency, SCIDX1.
Hum Mol Genet.
2
1993
1099
1104
142
Johnston
JA
Kawamura
M
Kirken
RA
et al
Phosphorylation and activation of the Jak-3 kinase in response to interleukin-2.
Nature.
370
1994
151
153
143
Pepper
AE
Buckley
RH
Small
TN
Puck
JM
Two mutational hotspots in the interleukin-2 receptor gene causing human X-linked severe combined immunodeficiency.
Am J Hum Genet.
57
1995
564
571
144
Disanto
JP
Muller
W
GuyGrand
D
Fischer
A
Rajewsky
K
Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γc chain.
Proc Natl Acad Sci U S A.
92
1995
377
381
145
Russell
SM
Tayebi
N
Nakajima
H
et al
Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development.
Science.
270
1995
797
800
146
Macchi
P
Villa
A
Gillani
S
et al
Mutations of Jak-3 gene in patients with autosomal severe combined immunodeficiency (SCID).
Nature.
377
1995
65
68
147
Kostmann
R
Infantile genetic agranulocytosis.
Acta Paediatr.
45(suppl 105)
1956
1
78
148
Kawaguchi
Y
Kobayashi
M
Tanabe
A
et al
Granulopoiesis in patients with congenital neutropenia.
Am J Hematol.
20
1985
223
234
149
Gillio
AP
Gabrilove
JL
Cytokine treatment of inherited bone marrow failure syndromes.
Blood.
81
1993
1669
1674
150
Kalra
R
Dale
D
Freedman
M
et al
Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia.
Blood.
86
1995
4579
4586
151
Dong
F
Brynes
RK
Tidow
N
Welte
K
Löwenberg
B
Touw
IP
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.
N Engl J Med.
333
1995
487
493
152
Dong
F
Dale
DC
Bonilla
MA
et al
Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia.
Leukemia.
11
1997
120
125
153
Welte
K
Touw
IP
G-CSF receptor mutations in patients with severe chronic neutropenia: a step in leukemogenesis [abstract].
Blood.
90
1997
433a
154
Hermans
MHA
Ward
AC
Antonissen
C
Karis
A
Lowenberg
B
Touw
IP
Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia.
Blood.
92
1998
32
39
155
Hermans
MHA
Antonissen
C
Ward
AC
Mayen
AEM
Ploemacher
RE
Touw
IP
Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene.
J Exp Med.
189
1999
683
692
156
Hunter
MG
Avalos
BR
Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia.
Blood.
93
1999
440
446
157
Rauprich
P
Kasper
B
Tidow
N
Welte
K
The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia.
Blood.
86
1995
4500
4505
158
Ward
AC
van Aesch
YM
Gits
J
et al
Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment.
J Exp Med.
190
1999
497
507
159
Youssoufian
H
Longmore
G
Neumann
D
Yoshimura
A
Lodish
HF
Structure, function and activation of the Epo receptor.
Blood.
81
1993
2223
2236
160
Arcasoy
MO
Harris
KW
Forget
BG
A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
Exp Hematol.
27
1999
63
74
161
De la Chapelle
A
Träskelin
AL
Juvonen
E
Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.
Proc Natl Acad Sci U S A.
90
1993
4495
4499
162
Sokol
L
Luhovy
M
Guan
Y
Prchal
JF
Semenza
GL
Prchal
IT
Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin.
Blood.
86
1995
15
22
163
Fanconi
G
Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.), I: clinical aspects.
Semin Hematol.
4
1967
233
240
164
Billardon
B
Moustacchi
E
Comparison of the sensitivity of Fanconi's anemia and normal fibroblasts of sister-chromatic exchanges by photoaddition of mono- and bi-functional psoralens.
Mutat Res.
174
1986
241
246
165
Whitney
MA
Royle
G
Low
MJ
et al
Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene.
Blood.
88
1996
49
58
166
Rathbun
RK
Faulkner
GR
Ostroki
MH
et al
Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
Blood.
90
1997
974
985
167
Pang
Q
Fagerlie
S
Christianson
TA
Keeble
W
Bagby
GC
The Fanconi anemia (FA) protein FAC is required for recruitment of Stat1 to the IFNγ receptor complex [abstract].
Blood.
92
1998
476a
168
Gutterman
JU
Cytokine therapeutics: lessons from interferon α.
Proc Natl Acad Sci U S A.
91
1994
1198
1205
169
Kuzel
TM
Roenigk
HH
Samuelson
E
et al
Effectiveness of interferon alpha-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome.
J Clin Oncol.
13
1995
257
263
170
Sun
WH
Pebon
C
Alsayed
Y
et al
Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression.
Blood.
91
1998
570
576
171
Wong
LH
Krauer
KG
Hatzinisiriou
I
et al
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ.
J Biol Chem.
272
1996
28,779
28,785
172
Sakamoto
H
Yasukawa
H
Masuhara
M
et al
A Janus kinase inhibitor, JAB, is an interferon-γ inducible gene and confers resistance to interferons.
Blood.
92
1998
1668
1676
173
Hoefsloot
LH
van Amelsvoort
MP
Broeders
LC
et al
Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.
Blood.
89
1997
1690
1700
174
Tabrizi
M
Yang
W
Jiao
H
et al
Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis.
Leukemia.
12
1998
200
206
175
Taylor
N
Uribe
L
Smith
S
Jahn
T
Kohn
DB
Weinberg
K
Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene.
Blood.
87
1996
3103
3107
176
Bunting
KD
Sangster
MY
Ihle
JN
Sorrentino
BP
Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer.
Nat Med.
4
1998
58
64
177
Chen
X
Vinkemeier
U
Zhao
Y
Jeruzalmi
D
Darnell
JE
Jr
Kuriyan
J
Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA.
Cell.
93
1998
827
839
178
Becker
S
Groner
B
Muller
CW
Three-dimensional structure of the Stat3 beta homodimer bound to DNA.
Nature.
394
1998
145
151
179
Kaplan
MH
Schindler
U
Smiley
ST
Grusby
MJ
Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells.
Immunity.
4
1996
313
319
180
Kaplan
MH
Wurster
AL
Grusby
MJ
A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells.
J Exp Med.
188
1998
1191
1196
181
Mui
AL-F
Wakao
H
Kinoshita
T
Kitamura
T
Miyajima
A
Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.
EMBO J.
15
1996
2425
2433
182
Matsumura
I
Ishikawa
J
Nakajima
K
et al
Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5.
Mol Cell Biol.
17
1997
2933
2943
183
Matsumura
I
Kitamura
T
Wakao
H
et al
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.
EMBO J.
18
1999
1367
1377
184
Shuai
K
Halpern
J
ten Hoeve
J
Rao
X
Sawyers
CL
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Oncogene.
13
1996
247
254
185
Chai
SK
Nichols
GL
Rothman
P
Constitutive activation of JAKs and STATs in BCR-Abl-ex-pressing cell lines and peripheral blood cells derived from leukemic patients.
J Immunol.
159
1997
4720
4728
186
Carlesso
N
Frank
DA
Griffin
JD
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
J Exp Med.
183
1996
811
820
187
Frank
DA
Varticovski
L
BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats.
Leukemia.
10
1996
1724
1730
188
Danial
NN
Pernis
A
Rothman
PB
Jak-STAT signalling induced by the v-abl oncogene.
Science.
269
1995
1875
1877
189
Yu
C-L
Jove
R
Burakoff
SJ
Constitutive activation of the Jak kinase-STAT pathway in T lymphoma overexpressing the lck protein tyrosine kinase.
J Immunol.
159
1997
5206
5210
190
Zhang
Q
Nowak
I
Vonderheid
EC
et al
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Proc Natl Acad Sci U S A.
93
1996
9148
9153
191
Nielsen
M
Kaktoft
K
Nordahl
M
et al
Constitutive activation of a slowly migrating isoform of STAT3 in mycosis fungoides: tyrphostin AG490 inhibits STAT3 activation and growth of mycosis fungoides tumor cell lines.
Proc Natl Acad Sci U S A.
94
1997
6764
6769
192
Lund
TC
Garcia
R
Medveczky
MM
Jove
R
Medveczky
PG
Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck.
J Virol.
71
1997
6677
6682
193
Weber-Nordt
RM
Egen
C
Wehinger
J
et al
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
Blood.
88
1996
809
816
194
Gouilleux-Gruart
B
Gouilleux
F
Desaint
C
et al
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.
Blood.
87
1996
1692
1697
195
Hayakawa
F
Towatari
M
Iida
H
et al
Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.
Br J Haematol.
101
1998
521
528
196
Xia
Z
Baer
MR
Block
AW
Baumann
H
Wetzler
M
Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts.
Cancer Res.
58
1998
3173
3180
197
Liu
R
Fan
C
Garcia
R
Jove
R
Zuckerman
KS
Constitutive activation of the JAK/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines.
Blood.
93
1999
2369
2379
198
Migone
T-S
Lin
J-X
Cereseto
A
et al
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.
Science.
269
1995
79
81
199
Takemoto
S
Mulloy
JC
Cereseto
A
et al
Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.
Proc Natl Acad Sci U S A.
94
1997
13,897
13,902
Sign in via your Institution